OncLive SOSS

Updates on HER2-Directed ADCs Across Solid Tumors - Episode 11

Managing ILD and Pneumonitis Risk From ADCs

August 8, 2024

Vijayakrishna Gadi, MD, University of Illinois College of Medicine, Susana Campos, MD, MPH, Matthew D. Galsky, MD, Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA, Aparna R. Parikh, MD

Vijayakrishna Gadi, MD, PhD, discusses the risk of ILD and pneumonitis from ADCs.

EP. 1: Assessing HER2 Status Across Tumor Types

EP. 2: ADCs Targeting HER2+ Breast Cancer

EP. 3: ADCs Targeting HER2+ Gynecologic Cancers

EP. 4: Emerging Data from ASCO 2024 in HER2-low: DESTINY-Breast06

EP. 5: ADCs Targeting GI Cancers

EP. 6: ADCs Targeting HER2+ Lung Cancer

EP. 7: Impact of ADCs on Brain Metastases

EP. 8: ADCs Targeting HER2+ GU Cancers

EP. 9: Overcoming Challenges of Testing for HER2-low Across Solid Tumor Types

EP. 10: The Potential Role for HER2-Targeted ADCs in Earlier Treatment Lines

EP. 11: Managing ILD and Pneumonitis Risk From ADCs

EP. 12: Managing Toxicities in Short- and Long-Term Treatment with ADCs

EP. 13: Managing Hematologic AEs Associated with ADC Treatments

EP. 14: Management of Emetogenicity of Antibody-Drug Conjugates

EP. 15: ADC Sequencing

EP. 16: Emerging ADCs in Development

EP. 17: Insights on T-DXd Approval as Tumor-Agnostic HER2-Directed Therapy

EP. 18: The Future for HER2-Directed ADCs

EP. 19: Key Takeaways and Closing Thoughts on ADCs

Video content above is prompted by the following:

What are the most common toxicities associated with ADCs? Which are most concerning for physicians? For patients?
What toxicities are of greatest concern for patients withgynecologic, GI, Lung ,and GU cancers?